Doctor Aarif Khakoo

Aarif Khakoo, M.D., M.B.A., is Chief Scientific Officer and Head of Research and Development (R&D) at Scribe Therapeutics. Prior to joining Scribe, Aarif served as Chief Medical Officer and Head of Drug Development at Calico Life Sciences, where he led the company's maturation into a clinical-stage company that filed multiple Investigational New Drug (IND) and Clinical Trial Applications (CTA) supporting its portfolio comprising more than 20 early- and late-stage compounds in cancer, neurological diseases, and tissue homeostasis and repair. Before joining Calico, Aarif held roles of increasing responsibility at Amgen that cemented his track record in drug development and fueled the company's emergence as a leader in cardiovascular and metabolic diseases. At Amgen, he created and led the Cardiometabolic Division, which delivered seven first-in-class new molecular entities for atherosclerosis, heart failure, and obesity. He then oversaw early clinical development as Head of Translational